Research programme: somatropin sustained-release - Samyang

Drug Profile

Research programme: somatropin sustained-release - Samyang

Alternative Names: hGH-PMP; hGH-SR - Samyang

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Growth disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Growth-disorders in South Korea (Parenteral, Controlled release)
  • 20 Aug 2012 Research programme: somatropin sustained-release - Samyang is available for licensing in World as of 20 Aug 2012. http://www.samyangbiopharm.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top